Compare Gilead Sciences, Inc. (GILD) vs Hasbro, Inc. (HAS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Hasbro, Inc. — how do they compare? Gilead Sciences, Inc. trades at $133.19 (market cap $163.51B), while Hasbro, Inc. trades at $81.92 (market cap $11.39B). The key difference: Gilead Sciences, Inc. is far larger — about 14.4× Hasbro, Inc.'s market cap, and Hasbro, Inc. pays the higher dividend (3.48%). Which is the better fit depends on your goals.
| GILD | HAS | |
|---|---|---|
Market Cap | $163.51B | $11.39B |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $105.88 |
52-Week Low | $108.22 | $70.95 |
Enterprise Value | $178.05B | $13.66B |
Dividend Yield | 2.49% | 3.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
Hasbro (HAS) trades at $78.42, down 1.4% on the day, with technical indicators showing a bearish trend while fundamentals reveal mixed signals. The company reported a net loss of $322.4M in 2025 despite beating earnings expectations for three consecutive quarters, with revenue of $4.7B and negative profit margins. Analyst consensus remains strongly positive with a $105.43 price target and no sell ratings among 33 analysts, though technical signals and recent stock performance suggest near-term pressure.
The investment case hinges on execution of Hasbro's 'aging up' strategy and Wizards segment growth against significant debt levels and profitability challenges. While Wall Street sees 34% upside to consensus targets, investors face risks from competitive pressures, high valuation multiples, and inconsistent earnings performance that could limit near-term appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Hasbro, Inc.
Hasbro is a branded play company providing children and families around the world with entertainment offerings based on a world-class brand portfolio. From toys and games to television programming, motion pictures, and a licensing program, Hasbro reaches customers by leveraging its well-known brands such as Transformers, Nerf, and Magic: The Gathering. Ownership stakes in Discovery Family, which offers programming around Hasbro brands, and owned production capabilities from Entertainment One help bolster Hasbro's multichannel presence. The firm acquired Entertainment One in 2019, bolting on popular properties like Peppa Pig and PJ Masks, and has plans to tie up with Dungeons & Dragons Beyond in 2022, offering the firm access 10 million digital tabletop players.
Read more on HAS →
